Who owns CASTLE BIOSCIENCES INC (CSTL)? Elite investor 13F holders
2 tracked elite investors reported holding CASTLE BIOSCIENCES INC as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | CASTLE BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 8853120.00 USD | 371200.000000 | Shares | reduce | Original filing |
| Tudor Investment | CASTLE BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| D.E. Shaw | CASTLE BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2690018.00 USD | 112789.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.